Clinical Trial Update: Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating velaglucerase alfa (VPRIV) on bone-related pathology in treatment-naïve adults with Type 1 Gaucher disease has completed, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• VPRIV (VELAGLUCERASE ALFA)

Snippet

Sponsor: Shire | Conditions: Gaucher Disease | Phase 4 | Status: COMPLETED | Results posted: 2022-02-01